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Abstract
Introduction The fixed-dose, long-acting bronchodilator
combination of umeclidinium/vilanterol (UMEC/VI) has not
previously been compared with a combination of a long-
acting muscarinic antagonist and long-acting b2-agonist in
patientswith chronic obstructive pulmonarydisease (COPD).
Methods This 12-week, randomized, blinded, triple-
dummy, parallel-group, non-inferiority study compared
once-daily UMEC/VI 62.5/25 mcg with once-daily
tiotropium (TIO) 18 mcg ? indacaterol (IND) 150 mcg in
patients with moderate-to-very-severe COPD. The primary
endpoint was the trough forced expiratory volume in 1 s
(FEV1) on day 85 (predefined non-inferiority margin
-50 mL), and the secondary endpoint was the 0- to 6-h
weighted mean (WM) FEV1 on day 84. Other efficacy
endpoints [including rescue medication use, the Transition
Dyspnea Index (TDI) focal score, and the St. George’s
Respiratory Questionnaire (SGRQ) score] and safety end-
points [adverse events (AEs), vital signs, and COPD
exacerbations] were also assessed.
Results Trough FEV1 improvements were comparable
between treatment groups [least squares (LS) mean changes
from baseline to day 85: UMEC/VI 172 mL; TIO ? IND
171 mL; treatment difference 1 mL; 95 % confidence interval
(CI) -29 to 30 mL], demonstrating non-inferiority between
UMEC/VI and TIO ? IND. The treatments produced similar
improvements in the trough FEV1 at other study visits and the
0- to 6-h WM FEV1 (LS mean changes at day 84: UMEC/VI
235 mL; TIO ? IND 258 mL; treatment difference-23 mL;
95 % CI -54 to 8 mL). The results for patient-reported
measures (rescue medication use, TDI focal score, and SGRQ
score) were comparable; both treatments produced clinically
meaningful improvements in TDI and SGRQ scores. The
incidence of AEs and COPD exacerbations, and changes in
vital signs were similar for the two treatments.
Conclusion UMEC/VI and TIO ? IND, given once
daily, provided similar improvements in lung function and
patient-reported outcomes over 12 weeks in patients with
COPD, with comparable tolerability and safety profiles.
Trial numbers ClinicalTrials.gov study IDNCT02257385;
GSK study no. 116961.
Key Points
The combination of umeclidinium/vilanterol was
considered non-inferior to tiotropium ? indacaterol
in terms of the primary lung function endpoint (the
trough forced expiratory volume in 1 s at day 85) on
the basis of a predefined non-inferiority margin.
The fixed-dose umeclidinium/vilanterol combination
and the free combination of tiotropium ? indacaterol,
given once daily, provided similar improvements in
lung function and patient-reported outcomes over
12 weeks in patients with chronic obstructive
pulmonary disease.
The treatments had similar tolerability and safety
profiles.
Electronic supplementary material The online version of this
article (doi:10.1007/s40268-016-0131-2) contains supplementary
material, which is available to authorized users.
& Chris Kalberg
chris.j.kalberg@gsk.com
1 GSK, PO Box 13398, Research Triangle Park, NC
27709-3398, USA
2 Respiratory Medicines Development Centre, GSK, Stockley
Park, Middlesex, UK
Drugs R D (2016) 16:217–227
DOI 10.1007/s40268-016-0131-2
1 Introduction
Long-acting bronchodilators are central to the pharmaco-
logical management of chronic obstructive pulmonary
disease (COPD) [1]. However, many patients remain
symptomatic despite the availability of effective long-act-
ing monotherapies. In a real-world study, Dransfield et al.
[2] reported that patients receiving tiotropium (TIO),
formoterol, or salmeterol as long-acting bronchodilator
maintenance therapy continued to report dyspnea and high
levels of supplemental rescue medication use, irrespective
of the level of airflow limitation.
Dual long-acting bronchodilator therapy represents an
alternative to long-acting bronchodilator monotherapy. The
fixed combination of the long-acting muscarinic antagonist
(LAMA) umeclidinium (UMEC) and the long-acting b2-
agonist (LABA) vilanterol (VI), at a dose of 62.5/25 mcg
once daily, is an approved maintenance treatment for
COPD in the USA, Canada, the EU, and several other
countries [3–5]. Dual bronchodilation with UMEC/VI has
been shown to provide greater improvements in lung
function than UMEC, VI, or TIO alone, with similar or
greater improvements in measures of dyspnea, rescue
medication use, and health-related quality of life (HRQoL)
[6–8]. However, a direct comparison between UMEC/VI
and another once-daily inhaled LAMA/LABA combination
has not been performed.
This is the first study to compare UMEC/VI 62.5/25 mcg
with a combination of a LAMA (TIO 18 mcg) and a
LABA [indacaterol (IND) 150 mcg] in patients with
moderate-to-very-severe COPD. TIO and IND are both
approved as single therapies for the maintenance treat-
ment of COPD [9–12]. TIO is a widely used and well-
characterized LAMA bronchodilator for the treatment of
COPD [1, 13], and once-daily IND at a dose of 150 mcg
has been shown to provide greater improvements in lung
function, symptoms, and HRQoL than placebo [14, 15].
IND 150 mcg is the approved dose in all countries apart




This was a multicenter, randomized, blinded, triple-
dummy, parallel-group study (GSK study no. 116961;
Clinicaltrials.gov study ID NCT02257385), conducted
between October 2014 and May 2015 at 86 centers across
Argentina, Chile, Estonia, France, Germany, Hungary,
Italy, Peru, Poland, Romania, the Russian Federation, and
Slovakia.
Patients meeting eligibility criteria at screening (visit 1)
entered a 5- to 7-day run-in period prior to randomization
at visit 2. The use of short-acting muscarinic antagonists,
inhaled corticosteroids (ICS), and albuterol were permitted
during the run-in period. Eligible patients were then ran-
domized to one of two treatments (UMEC/VI or
TIO ? IND) over a 12-week period. Clinic visits took
place on days 2, 14, 28, 56, 84, and 85, with a follow-up
period of approximately 7 days. The total duration of the
study was approximately 14 weeks.
The study was approved by a national, regional, or
investigational center ethics committee/institutional review
board in each country and was performed in accordance
with the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuti-
cals for Human Use Good Clinical Practice (ICH-GCP)
guidelines [16], all applicable subject privacy require-
ments, and the ethical principles outlined in the Declaration
of Helsinki, 2013 [17]. Written, informed consent was
obtained from all patients who participated in the study.
2.2 Patients
Eligible patients were male or female; were C40 years of
age; had an established clinical history of COPD (in accor-
dance with the American Thoracic Society/European Res-
piratory Society criteria [18]); were current or former
cigarette smokers with a history of cigarette smoking ofC10
pack-years; had pre- and post-bronchodilator forced expi-
ratory volume in 1 s (FEV1) values of B70 % predicted
normal; had pre- and post-bronchodilator FEV1/forced vital
capacity (FVC) ratios of\0.70; had a score of C2 on the
modifiedMedical Research Council Dyspnea Scale; and had
a corrected QT (QTc) interval (corrected for the heart rate,
according to Fridericia’s formula) of\450 or\480 ms for
patients with bundle branch block.
Patients were excluded from the study if they were of
childbearing potential (unless they were practicing
acceptable birth control methods); had a current diagnosis
of asthma; had alpha-1 antitrypsin deficiency, an active
lung infection (such as tuberculosis), lung cancer, or
another clinically significant disease/abnormality; had an
abnormal or significant electrocardiogram finding; had a
history of allergy or hypersensitivity to any anticholinergic,
muscarinic receptor antagonist, b2-agonist, lactose/milk
protein, or magnesium stearate; had been hospitalized for
COPD or pneumonia within 12 weeks prior to visit 1; had
undergone lung volume reduction surgery within
12 months prior to visit 1; were receiving long-term oxy-
gen therapy; had received any of the prohibited medica-
tions listed in Table S1 in the Electronic Supplementary
Material; or were in the acute phase of a pulmonary
rehabilitation program. The use of ICS/LABAs,
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phosphodiesterase-4 inhibitors, theophyllines, oral b2-ag-
onists, LAMAs, LABAs, and LAMA/LABA combinations
(other than those under study) was not allowed.
Patients were randomized to treatment only if they had
not experienced COPD exacerbation between visits 1
and 2, and if they had not used any prohibited medication
during the run-in period or at visit 2.
2.3 Treatments
Patients were randomized in accordance with a centralized
randomization schedule, using a randomization code gen-
erated by a validated computerized system (RandAll
Version NG, GSK). Patients were randomized using an
interactive voice recognition system.
Patients meeting the eligibility criteria were randomized
1:1 to receive UMEC/VI 62.5/25 mcg once daily via an
ELLIPTATM dry powder inhaler ? placebo once daily via
a HandiHaler ? placebo once daily via a Breezhaler, or
TIO 18 mcg once daily via a HandiHaler ? IND
150 mcg once daily via a Breezhaler ? placebo once
daily via an ELLIPTATM.
Patients were instructed to take one dose each morning
from theELLIPTATM, theHandiHaler, and theBreezhaler.
All patients had albuterol provided for as-needed use.
A triple-dummy study design was used to achieve study
blinding, whereby patients were given three inhalers con-
taining either an active drug or placebo. All patients and
investigators were blinded to the assigned treatment during
the study. However, exact physical placebo matches for the
TIO and IND capsules and for the IND blister packs were not
available, although they were closely matched in color. As
the studywas of a parallel-group design, the capsule typewas
consistent for each patient for the duration of the study. Both
the TIO and IND blister packages containing the capsules
were coveredwith opaque over-labels. TheHandiHaler and
Breezhaler devices were covered with labels to mask
identifying markings. The study medication was prepared
and provided to the patient by study personnel who were
independent of safety and efficacy procedures.
2.4 Outcomes and Assessments
2.4.1 Efficacy Endpoints
The primary objective of the study was to determine
whether the efficacy of UMEC/VI was non-inferior to that
of TIO ? IND as assessed by the trough FEV1 at day 85
(the primary endpoint was the trough FEV1 at day 85,
defined as the mean of the FEV1 values obtained at 23 and
24 h after dosing on day 84). The secondary endpoint of
the study was the weighted mean (WM) FEV1 over 0–6 h
postdose at day 84, calculated from the predose FEV1
values (obtained 30 and 5 min before dosing) and the
postdose FEV1 measurements at 1, 3, and 6 h.
Other efficacy endpoints included the trough FEV1 at
days 28 and 56; 0- to 6-h WM FEV1 at day 1; 0- to 6-h
serial FEV1 at days 1 and 84; serial and trough FVC; mean
number of puffs of rescue medication per day over
days 1–84; percentage of rescue-free days over days 1–84;
Transition Dyspnea Index (TDI) focal score and proportion
of TDI responders at days 28, 56, and 84 (defined as
patients with a TDI focal score of C1 unit [19]); and
St. George’s Respiratory Questionnaire (SGRQ) score and
proportion of responders at days 28, 56, and 84 (defined as
having a total SGRQ score C4 units below baseline [20]).
TDI and SGRQ assessments were performed prior to
spirometry testing. Patients used a paper diary to record
their rescue medication use in the previous 24 h.
Safety assessments took into account the incidence rates
of adverse events (AEs), vital signs, and COPD exacer-
bations. AEs and COPD exacerbations (defined as wors-
ening of COPD symptoms, requiring use of additional
treatment other than the prescribed bronchodilator, such as
antibiotics, systemic corticosteroids, and/or emergency
treatment or hospitalization) were assessed throughout the
study. Vital signs (the pulse rate and systolic and diastolic
blood pressure) were assessed at screening and either at
day 85 or at an early withdrawal visit.
2.5 Statistical Analysis
The sample size calculations used a one-sided 2.5 % sig-
nificance level and an estimated residual standard deviation
for the trough FEV1 of 220 mL, based on a mixed-model
repeated measures (MMRM) analysis of previous studies in
patients with COPD (GSK; data on file). A study with 760
evaluable patients for the primary analysis would have
88 % power to detect non-inferiority of UMEC/VI to
TIO ? IND on the trough FEV1, when the margin of non-
inferiority was -50 mL. If the lower limit of the 95 %
confidence interval (CI) fell above -50 mL but below 0,
then UMEC/VI could be considered statistically non-infe-
rior to TIO ? IND.
The intent-to-treat (ITT) population comprised all
patients randomized to treatment who received at least one
dose of randomized studymedication, while the per-protocol
(PP) population comprised all patients in the ITT population
who were not identified as full protocol deviators.
The PP population was used for treatment comparisons
of the primary endpoint of the trough FEV1 at day 85, as
use of the ITT population (and inclusion of data from
protocol deviators) would tend to bias the results toward
equivalence. This could potentially make an inferior
treatment appear non-inferior [21]. The approach used in
the present study has also been used in other non-inferiority
Umeclidinium/Vilanterol vs Tiotropium ? Indacaterol in COPD 219
COPD studies [22, 23] and was intended to maximize true
differences between treatments. The ITT population was
used for comparisons of the secondary and other efficacy
endpoints, as well as safety endpoints. This approach was
employed because the study was not designed to detect
non-inferiority on the other endpoints; therefore, the ITT
population was used because it followed the randomization
procedure [24, 25].
It was estimated that approximately 10 % of patients
providing an assessment at day 84 would be excluded from
the PP population, giving 844 evaluable patients for the
ITT analysis, with [90 % power. With allowance for a
12 % withdrawal rate, it was planned that a total of 960
patients would be randomized.
The efficacy parameters were assessed using MMRM
analysis, with the exception of the proportions of TDI and
SGRQ responders (assessed using a logistic regression
model), and the percentage of rescue-free days over
weeks 1–12 (assessed using a non-parametric analysis).
3 Results
3.1 Patients
Of the 1190 patients enrolled, 967 were randomly assigned
to treatment (distribution by country is shown in Table S2
in the Electronic Supplementary Material). The ITT pop-
ulation comprised 961 patients, as six patients were ran-
domized in error and did not receive study medication. The
majority of these patients (96 %) were included in the PP
population, which comprised 918 patients (UMEC/VI,
n = 463; TIO ? IND, n = 455). In total, 917 patients
(95 %) completed the study. The most common reason for
study withdrawal was AEs, which accounted for a similar
proportion of patients withdrawing from each treatment
group [UMEC/VI, n = 12 (2 %); TIO ? IND, n = 8
(2 %)] (Fig. 1).
Patients in the ITT population had moderate-to-very-
severe COPD [Global initiative for chronic Obstructive
Lung Disease (GOLD) stage 2–4, primarily GOLD grades
B and D], and the majority of patients were male and white
(Table 1). The baseline demographics and clinical char-
acteristics of the ITT and PP populations were similar.
3.2 Efficacy
3.2.1 Lung Function
In the two treatment groups, similar improvements from
baseline were observed for the primary endpoint of the
trough FEV1 at day 85, with a difference of ?1 mL for
UMEC/VI versus TIO ? IND (95 % CI -29 to 30 mL; PP












Adverse event, n=12 (2%)
Protocol deviation, n=5 (1%)
Withdrew consent, n=4 (<1%)





Adverse event, n=8 (2%)
Protocol deviation, n=7 (1%)
Withdrew consent, n=4 (<1%)
Lack of efficacy, n=2 (<1%)








Pre-screening, screening or run-in failures
N=229
(Pre-screen failure, n=47; screen failures: did not meet
inclusion/exclusion criteria, n=139, withdrew consent, n=7,
adverse event, n=1; run-in failures: withdrew consent, n=14,
did not meet continuation criteria, n=14, adverse event,
n=6, study closed/terminated, n=1)
Fig. 1 Summary of patient disposition. Asterisk six patients were randomized in error and are included in the screening failure and run-in failure
rates. IND indacaterol, TIO tiotropium, UMEC umeclidinium, VI vilanterol
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the prespecified non-inferiority margin of -50 mL,
demonstrating non-inferiority of the two treatments. Sim-
ilar improvements from baseline in the trough FEV1 were
observed at all time points with UMEC/VI and TIO ? IND
(Fig. 2). Similar results for the trough FEV1 at day 85 were
observed in the ITT population [treatment difference for
UMEC/VI versus TIO ? IND: 7 mL (95 % CI -22 to
35 mL)].
The mean changes from baseline in the 0- to 6-h WM
FEV1 at day 84 (the secondary endpoint) also showed
similar improvements with UMEC/VI versus TIO ? IND
treatment [day 84 difference -23 mL (95 % CI -54 to
8 mL); ITT population] (Table 2).
The mean serial FEV1 values showed a consistent pat-
tern of improvement versus baseline in both treatment
groups at days 1 and 84 (see Fig. S1a, b in the Electronic
Supplementary Material).
The improvement from baseline in the mean trough
FVC values was comparable in the UMEC/VI and
TIO ? IND treatment groups at all time points from day 2
through to day 85 (Fig. 3; Table 2). Serial FVC measure-
ments also showed a consistent pattern of improvement
versus baseline in both treatment groups at days 1 and 84
(see Fig. S2a, b in the Electronic Supplementary Material).
3.2.2 Rescue Medication Use
The least squares (LS) mean changes from baseline in
rescue medication use were similar in the UMEC/VI and
TIO ? IND treatment groups over weeks 1–12 [difference







Mean age [years (SD)] 64 (7.75) 64 (8.44)
Male [n (%)] 355 (74) 341 (71)
Race [n (%)]
White 453 (94) 450 (94)
American Indian or Alaska native 24 (5) 27 (6)
Asian 5 (1) 2 (\1)
Current smoker at screening [n (%)] 198 (41) 218 (46)
Mean smoking pack-years (SD)a 43.17 (22.71) 42.30 (23.12)
ICS use at screening [n (%)] 269 (56) 243 (51)
Post-albuterol FEV1 [L; mean (SD)]
b 1.369 (0.46) 1.357 (0.48)
Post-albuterol FEV1/FVC [mean (SD)]
b 45.70 (11.09) 45.55 (11.12)
Reversible with albuterol [n (%)]c,d 126 (26) 125 (26)
% Reversibility with albuterol [mean (SD)]c,d 12.2 (13.06) 12.5 (12.87)
GOLD category [n (%)]b
II 209 (44) 200 (42)
III 222 (46) 220 (46)
IV 48 (10) 57 (12)
GOLD grade according to CAT [n (%)]e
A: low risk, less symptoms 26 (5) 19 (4)
B: low risk, more symptoms 139 (29) 146 (31)
C: high risk, less symptoms 22 (5) 25 (5)
D: high risk, more symptoms 293 (61) 287 (60)
Mean BDI focal score (SD) 5.9 (1.89) 6.0 (1.67)
BDI Baseline Dyspnea Index, CAT COPD assessment test, COPD chronic obstructive pulmonary disease,
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global initiative for chronic
Obstructive Lung Disease, ICS inhaled corticosteroid, IND indacaterol, SD standard deviation, TIO tio-
tropium, UMEC umeclidinium, VI vilanterol
a Smoking pack-years = (number of cigarettes smoked per day/20) 9 number of years of smoking
b UMEC/VI, n = 479; TIO ? IND, n = 477
c Reversibility was defined as an increase in the FEV1 of C12 % and C200 mL following administration of
albuterol
d UMEC/VI, n = 477; TIO ? IND, n = 477
e UMEC/VI, n = 480; TIO ? IND, n = 477
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0.1 puffs (95 % CI -0.1 to 0.3)] (Table 3), and no dif-
ference was detected in the percentages of rescue-free days
over weeks 1–12 in the two treatment groups [median
difference 0 days (95 % CI 0 to 2.6); Hodges Lehmann
estimate and Wilcoxon rank sum test].
3.2.3 Symptoms and Health-Related Quality of Life
The mean TDI focal scores and the proportions of
responders based on the TDI score were similar with the
two treatments throughout the study (Table 3). The LS
mean TDI scores at day 84 were 2.32 and 2.62 in patients
receiving UMEC/VI and TIO ? IND, respectively
(Table 3). Additionally, UMEC/VI and TIO ? IND resul-
ted in comparable improvements from baseline in SGRQ
scores and the proportion of responders (having a total
SGRQ score C4 units below baseline) at all assessments
(Table 3). UMEC/VI and TIO ? IND resulted in LS mean
changes from the baseline SGRQ scores of -4.93 and -
5.01 points, respectively (Table 3).
3.3 Safety
The overall incidence of on-treatment AEs during the study
was generally similar in the two treatment groups, with
headache and nasopharyngitis reported most frequently.
Table 2 Summary of lung function endpoints
UMEC/VI, PP population,
N = 463
TIO ? IND, PP population,
N = 455
Trough FEV1 [mL; PP population]
Day 85 n = 392 n = 392
LS mean change from baseline (SE) 172 (11) 171 (11)
Difference (95 % CI) 1 (-29 to 30)
0- to 6-h WM FEV1 [L; ITT population]
Day 1 n = 478 n = 471
LS mean change from baseline (SE) 184 (7) 185 (7)
Difference (95 % CI) -1 (-20 to 18)
Day 84 n = 455 n = 452
LS mean change from baseline (SE) 235 (11) 258 (11)
Difference (95 % CI) -23 (-54 to 8)
Trough FVC [mL; ITT population]
Day 85 n = 455 n = 455
LS mean change from baseline (SE) 239 (18) 220 (18)
Difference (95 % CI) 20 (-29 to 68)
CI confidence interval, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, IND indacaterol, ITT intent-to-treat, LS least squares,






























Fig. 2 Least squares (LS) mean
[95 % confidence interval (CI)]
changes from baseline in the
trough forced expiratory volume
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There were low incidence rates of non-fatal serious AEs
and AEs leading to study withdrawal in both the UMEC/VI
and TIO ? IND treatment groups (Table 4).
Five deaths occurred on-treatment during the study
(UMEC/VI: n = 4, \1 %; TIO ? IND: n = 1, \1 %),
including one fatal event of pneumonia and respiratory
failure in the UMEC/VI treatment group (onset at day 77)
and one fatal event of pneumonia in the TIO ? IND
treatment group (onset at day 72). The three other deaths in
the UMEC/VI treatment group were related to individual
events of ventricular fibrillation (onset at day 76), circu-
latory collapse (onset at day 7), and cardiac arrest (onset at
day 41).
The three deaths relating to ventricular fibrillation,
cardiac arrest, and pneumonia in the UMEC/VI treatment
group occurred C14 days after the last dose of study
medication, as recorded in the electronic case report forms.
The death relating to cardiac arrest was reported as a
sudden event, occurring with exertion 41 days after the first
dose. The cardiac arrest was reported by the investigator as
being related to the study medication. No other deaths were
identified by the study investigators as being related to the
study medication.
The incidence rates of COPD exacerbations were low
and the same in both groups (10 %; Table 4). The mean
changes in vital signs were small and similar in the two
treatments groups (data not shown).
4 Discussion
Previous studies have shown that UMEC/VI provides
greater improvements in lung function than UMEC, VI, or
TIO alone, with similar or greater improvements in mea-
sures of dyspnea, rescue medication use, and HRQoL
[6–8]. This is the first clinical trial to evaluate UMEC/VI in
comparison with another combination of a LAMA and
LABA—specifically, co-administration of TIO and IND,
both of which are well-characterized, once-daily, long-
acting bronchodilators indicated for COPD [13–15]. As
both treatments comprised a LAMA and LABA, it was
anticipated that the combinations would have comparable
beneficial effects on the trough FEV1. The study was
therefore designed to test for non-inferiority for the pri-
mary efficacy measure of the trough FEV1.
UMEC/VI was shown to be non-inferior to TIO ? IND
by the prespecified non-inferiority margin (-50 mL) for
the trough FEV1 at day 85, with similar magnitudes of
improvement from baseline being shown with the two
treatments. The LS mean treatment differences between the
two treatment groups were also similarly small at all other
evaluations of the trough FEV1. The trough FEV1 results,
obtained at the end of the once-daily dosing interval, were
supported by similar findings in the two treatment groups
for evaluations of the initial bronchodilator effect, as
measured by serial FEV1 assessments obtained over the
first 6 h postdose and the 0- to 6-h WM FEV1, indicating
similar peak effects and onsets of action.
The improvements in lung function measures were
paralleled by comparable improvements in patient-reported
measures of dyspnea, HRQoL, and rescue medication use.
For the assessment of dyspnea, both treatments produced a
TDI score that exceeded 1 unit [the minimum clinically
important difference (MCID) [19] at all assessments].
Improvements in HRQoL were indicated by a total SGRQ
score C4 units below baseline (the established MCID for
the SGRQ [20]) from day 28 onwards for UMEC/VI, and
from day 56 onward for TIO ? IND. These findings sup-
port the results of other randomized controlled trials, in
which UMEC/VI treatment led to clinically meaningful






























Fig. 3 Least squares (LS) mean
[95 % confidence interval (CI)]
changes from baseline in the
trough forced vital capacity
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Days 1–84 n = 474 n = 472
LS mean change in mean puffs per day from baseline (SE) -1.5 (0.06) -1.4 (0.06)
Difference (95 % CI) 0.1 (-0.1 to 0.3)
TDI focal score
Day 28 n = 470 n = 461
LS mean change from baseline (SE) 2.07 (0.12) 2.02 (0.12)
Difference (95 % CI) 0.05 (-0.29 to 0.39)
Day 56 n = 462 n = 459
LS mean change from baseline (SE) 2.08 (0.12) 2.14 (0.12)
Difference (95 % CI) -0.05 (-0.38 to 0.28)
Day 84 n = 459 n = 455
LS mean change from baseline (SE) 2.32 (0.13) 2.62 (0.13)
Difference (95 % CI) -0.30 (-0.65 to 0.05)
Proportion of responders according to TDI scorea
Day 28 n = 478 n = 471
Responders [n (%)] 302 (63) 295 (63)
Odds ratio (95 % CI) 1.01 (0.77 to 1.33)
Day 56 n = 477 n = 474
Responders [n (%)] 287 (60) 289 (61)
Odds ratio (95 % CI) 0.95 (0.73 to 1.25)
Day 84 n = 478 n = 476
Responders [n (%)] 298 (62) 309 (65)
Odds ratio (95 % CI) 0.88 (0.67 to 1.16)
SGRQ total score
Day 28 n = 461 n = 456
LS mean change from baseline (SE) -4.41 (0.50) -3.28 (0.50)
Difference (95 % CI) -1.12 (-2.50 to 0.26)
Day 56 n = 448 n = 458
LS mean change from baseline (SE) -5.26 (0.54) -4.89 (0.53)
Difference (95 % CI) -0.37 (-1.86 to 1.12)
Day 84 n = 450 n = 453
LS mean change from baseline (SE) -4.93 (0.58) -5.01 (0.57)
Difference (95 % CI) 0.08 (-1.52 to 1.67)
Proportion of responders according to SGRQ total scoreb
Day 28 n = 470 n = 466
Responders [n (%)] 210 (45) 185 (40)
Odds ratio (95 % CI) 1.19 (0.92 to 1.55)
Day 56 n = 464 n = 472
Responders [n (%)] 229 (49) 224 (47)
Odds ratio (95 % CI) 1.04 (0.80 to 1.35)
Day 84 n = 471 n = 476
Responders [n (%)] 223 (47) 216 (45)
Odds ratio (95 % CI) 1.05 (0.81 to 1.37)
CI confidence interval, IND indacaterol, LS least squares, SE standard error, SGRQ St. George’s Respiratory Questionnaire, TDI Transition
Dyspnea Index, TIO tiotropium, UMEC umeclidinium, VI vilanterol
a TDI focal score of C1 unit
b Proportion of responders is defined by a difference of -4 units or lower from the visit score to the baseline score
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TIO and IND were chosen as open dual comparators in
the present study as they were the only two once-daily
LAMA and LABA medications approved for COPD at the
time of the study initiation. TIO is also a well-characterized
LAMA bronchodilator for the treatment of COPD [1, 13],
and IND 150 mcg once daily has been shown to improve
lung function, symptoms, and HRQoL in comparison with
placebo [14, 15]. Although TIO administered via a
HandiHaler is approved at a single dose of 18 mcg once
daily, IND is approved at multiple doses; an IND dose of
150 mcg was selected in the present study as this is the
approved dose in all countries apart from the USA, where
the recommended dose is 75 mcg [11, 12]. As additional
LABA and LAMA monotherapies and LAMA/LABA
fixed-dose combinations are now available for the treat-
ment of COPD [1], further head-to-head studies will be
required to evaluate the comparative safety and efficacy of
other combinations.
Previous studies have shown that UMEC/VI have
tolerability and safety profiles similar to those of UMEC,
VI, and TIO alone, and placebo [6–8]. In this study, both
UMEC/VI and TIO ? IND were generally well tolerated,
with AEs consistent with the patient population under
study. The incidence of dry mouth was low (1 % in each
treatment group), and cough was reported in 3 and 4 %
of UMEC/VI and TIO ? IND patients, respectively. The
incidence rates of cardiovascular events of special
interest—which included AE terms for cardiac arrhyth-
mias, cardiac failure, ischemic heart disease, and hem-
orrhages—were low and the same in the two groups
(2 % of patients). The incidence rates of death were
similar in the two groups (\1 %), although there was a
numerical imbalance in the number of deaths reported in
the UMEC/VI group (n = 4) compared with the
TIO ? IND group (n = 1). Overall, the nature of the
events was consistent with the population under study.
Interpretation of the imbalance is limited because of the
small number of fatal events overall and the confounding
of three events in the UMEC/VI group, for which the
event date was reported as C14 days after the last dose
of the study medication.
A limitation of this study was the imperfect blinding to
the study medications, as exact physical matches for the
TIO and IND capsules were not available. However,
safeguards were in place to prevent the unblinding of study
personnel, and study blinding coordinators independent of
other clinical trial procedures were involved in the prepa-
ration and administration of treatment to patients.
5 Conclusion
This study demonstrated that treatment over 12 weeks with
UMEC/VI 62.5/25 mcg once daily resulted in improve-
ments in measures of lung function, symptoms, and health
status similar to those achieved with the free combination
of TIO 18 mcg ? IND 150 mcg once daily in patients with
moderate-to-very-severe COPD, with comparable safety
profiles.
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